• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

紫龙金片治疗非小细胞肺癌的荟萃分析及其抗非小细胞肺癌和 COVID-19 的网络药理学作用

A meta-analysis of the Zilongjin tablets for non-small cell lung cancer and its network pharmacology of action against NSCLC and COVID-19.

作者信息

Yang Wuxia, Zhang Yichao, Gao Jing, Hu Pengcheng, Yang Yanjie, Xu Xiaoqing

机构信息

The Graduate School, Tianjin Medical University, Tianjin, China.

The Graduate School, Qinghai University, Xining, China.

出版信息

Front Med (Lausanne). 2023 Aug 1;10:1080121. doi: 10.3389/fmed.2023.1080121. eCollection 2023.

DOI:10.3389/fmed.2023.1080121
PMID:37593408
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10427870/
Abstract

OBJECTIVE

To objectively evaluate the efficacy of the Zilongjin tablets in non-small cell lung cancer (NSCLC) and to explore its potential mechanism of action against NSCLC and COVID-19 based on network pharmacology.

METHODS

The database was searched for randomized controlled trials (RCTs) of the Zilongjin tablets for NSCLC published up to 22 August 2022. The quality of included trials was assessed using Cochrane standard guidelines, and a meta-analysis was performed using Rev Man 5.3. Gene targets for intersections of NSCLC and COVID-19 (the NC) and drugs were obtained from the TCMSP database, HERB database, GeneCards database, and the NCBI database for network pharmacology research.

RESULTS

Meta-analysis included 14 articles with 2,430 patients. The meta-analysis showed that the Zilongjin tablets combined with conventional chemotherapy were significantly more effective than chemotherapy alone in the treatment of NSCLC. A total of 29 drug-disease intersecting targets were identified in the network pharmacology. The "ingredient-target-pathway" diagram component-target-pathway network contained 119 nodes and 429 edges, with the majority of targets associated with inflammatory responses.

CONCLUSION

The efficacy and quality of life of the Zilongjin tablets combined conventional chemotherapy for NSCLC were significantly better than chemotherapy alone, alleviating various adverse effects. At the same time, the Zilongjin tablets may modulate the inflammatory response to alleviate NSCLC and COVID-19.

摘要

目的

客观评价紫龙金片治疗非小细胞肺癌（NSCLC）的疗效，并基于网络药理学探讨其抗NSCLC及新型冠状病毒肺炎（COVID-19）的潜在作用机制。

方法

检索截至2022年8月22日已发表的关于紫龙金片治疗NSCLC的随机对照试验（RCT）。采用Cochrane标准指南评估纳入试验的质量，并使用Rev Man 5.3进行荟萃分析。从中药系统药理学数据库（TCMSP数据库）、中药综合数据库（HERB数据库）、基因卡片数据库（GeneCards数据库）和美国国立生物技术信息中心数据库（NCBI数据库）获取NSCLC与COVID-19交集（NC）的基因靶点及药物，用于网络药理学研究。

结果

荟萃分析纳入14篇文章，共2430例患者。荟萃分析表明，紫龙金片联合传统化疗治疗NSCLC的疗效显著优于单纯化疗。网络药理学共鉴定出29个药物-疾病交集靶点。“成分-靶点-通路”图组件-靶点-通路网络包含119个节点和429条边，大多数靶点与炎症反应相关。

结论

紫龙金片联合传统化疗治疗NSCLC的疗效及生活质量显著优于单纯化疗，可减轻各种不良反应。同时，紫龙金片可能通过调节炎症反应来缓解NSCLC及COVID-19。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/21daa27b443e/fmed-10-1080121-g0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/268512b4f378/fmed-10-1080121-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/8b975df01c9d/fmed-10-1080121-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/e72d29436bee/fmed-10-1080121-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/82b4089c0831/fmed-10-1080121-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/e96db4ad90da/fmed-10-1080121-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/bdea9768c9bb/fmed-10-1080121-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/6ecbebc44635/fmed-10-1080121-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/14dc295f00ae/fmed-10-1080121-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/5574fb0028d5/fmed-10-1080121-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/6babbaa5d545/fmed-10-1080121-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/e3505d935432/fmed-10-1080121-g0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/21daa27b443e/fmed-10-1080121-g0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/268512b4f378/fmed-10-1080121-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/8b975df01c9d/fmed-10-1080121-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/e72d29436bee/fmed-10-1080121-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/82b4089c0831/fmed-10-1080121-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/e96db4ad90da/fmed-10-1080121-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/bdea9768c9bb/fmed-10-1080121-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/6ecbebc44635/fmed-10-1080121-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/14dc295f00ae/fmed-10-1080121-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/5574fb0028d5/fmed-10-1080121-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/6babbaa5d545/fmed-10-1080121-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/e3505d935432/fmed-10-1080121-g0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f01c/10427870/21daa27b443e/fmed-10-1080121-g0012.jpg

相似文献

1
A meta-analysis of the Zilongjin tablets for non-small cell lung cancer and its network pharmacology of action against NSCLC and COVID-19.紫龙金片治疗非小细胞肺癌的荟萃分析及其抗非小细胞肺癌和 COVID-19 的网络药理学作用
Front Med (Lausanne). 2023 Aug 1;10:1080121. doi: 10.3389/fmed.2023.1080121. eCollection 2023.
2
Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis.七味中药联合化疗治疗非小细胞肺癌的网状 Meta 分析。
Pharm Biol. 2024 Dec;62(1):404-422. doi: 10.1080/13880209.2024.2351940. Epub 2024 May 13.
3
["Multi-component-multi-target-multi-pathway" mechanism of Kuihua Hugan Tablets based on network pharmacology].基于网络药理学的葵花护肝片“多成分-多靶点-多通路”作用机制
Zhongguo Zhong Yao Za Zhi. 2019 Apr;44(7):1464-1474. doi: 10.19540/j.cnki.cjcmm.20181214.003.
4
Clinical efficacy and potential mechanism of ginseng polysaccharides in the treatment of non-small cell lung cancer based on meta-analysis associated with network pharmacology.基于网络药理学相关Meta分析的人参多糖治疗非小细胞肺癌的临床疗效及潜在机制
Heliyon. 2024 Mar 7;10(6):e27152. doi: 10.1016/j.heliyon.2024.e27152. eCollection 2024 Mar 30.
5
Identification of phytochemical compounds of and their targets by metabolomics, network pharmacology and molecular docking studies.通过代谢组学、网络药理学和分子对接研究鉴定[具体物质]的植物化学化合物及其靶点。
Heliyon. 2023 Mar;9(3):e14029. doi: 10.1016/j.heliyon.2023.e14029. Epub 2023 Mar 1.
6
Network Pharmacology Analysis to Explore the Pharmacological Mechanism of Effective Chinese Medicines in Treating Metastatic Colorectal Cancer using Meta-Analysis Approach.基于Meta分析方法的网络药理学分析以探究有效中药治疗转移性结直肠癌的药理机制
Am J Chin Med. 2021;49(8):1839-1870. doi: 10.1142/S0192415X21500877. Epub 2021 Nov 15.
7
The Effect of on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology.基于网络和实验药理学的研究：探讨 对非小细胞肺癌的影响。
Biomed Res Int. 2023 Jan 23;2023:6407588. doi: 10.1155/2023/6407588. eCollection 2023.
8
[Blaps rynchopetera affects proliferation, migration, and invasion of non-small cell lung cancer: a study based on network pharmacology and in vivo and in vitro experiments].[拟步甲影响非小细胞肺癌的增殖、迁移和侵袭：一项基于网络药理学及体内外实验的研究]
Zhongguo Zhong Yao Za Zhi. 2023 Jul;48(13):3576-3588. doi: 10.19540/j.cnki.cjcmm.20230202.702.
9
Molecular mechanism of Rhubarb in the treatment of non-small cell lung cancer based on network pharmacology and molecular docking technology.基于网络药理学和分子对接技术的大黄治疗非小细胞肺癌的分子机制。
Mol Divers. 2023 Jun;27(3):1437-1457. doi: 10.1007/s11030-022-10501-w. Epub 2022 Aug 6.
10
The mechanism of Bai He Gu Jin Tang against non-small cell lung cancer revealed by network pharmacology and molecular docking.网络药理学和分子对接揭示百合固金汤治疗非小细胞肺癌的作用机制。
Medicine (Baltimore). 2022 Dec 30;101(52):e32555. doi: 10.1097/MD.0000000000032555.

引用本文的文献

1
Regulation of the tumor microenvironment by Traditional Chinese Medicine: current progress and future perspectives in oncology.中医药对肿瘤微环境的调控：肿瘤学的当前进展与未来展望
Am J Transl Res. 2025 Jun 15;17(6):4071-4086. doi: 10.62347/NOAI4101. eCollection 2025.
2
Mechanism of Qingchang compound against coccidiosis based on network pharmacology-molecular docking.基于网络药理学-分子对接的清肠复方抗球虫病作用机制
Front Vet Sci. 2024 Mar 1;11:1361552. doi: 10.3389/fvets.2024.1361552. eCollection 2024.

本文引用的文献

1
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as mortality predictor of advanced stage non-small cell lung cancer (NSCLC) with COVID-19 in Indonesia.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值可预测印度尼西亚合并 COVID-19 的晚期非小细胞肺癌（NSCLC）患者的死亡率。
Eur Rev Med Pharmacol Sci. 2021 May;25(10):3868-3878. doi: 10.26355/eurrev_202105_25954.
2
Severity of COVID-19 in patients with lung cancer: evidence and challenges.肺癌患者 COVID-19 的严重程度：证据与挑战。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002266.
3
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
非小细胞肺癌患者一线纳武利尤单抗联合伊匹单抗加两个周期化疗（CheckMate 9LA）：一项国际、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18.
4
The impact of the COVID-19 pandemic on lung cancer patients.2019年冠状病毒病大流行对肺癌患者的影响。
Ann Palliat Med. 2020 Sep;9(5):3373-3378. doi: 10.21037/apm-20-1662.
5
Covid-19 and lung cancer: A greater fatality rate?Covid-19 与肺癌：更高的死亡率？
Lung Cancer. 2020 Aug;146:19-22. doi: 10.1016/j.lungcan.2020.05.034. Epub 2020 May 30.
6
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.COVID-19 对癌症患者的临床影响（CCC19）：一项队列研究。
Lancet. 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9. Epub 2020 May 28.
7
Real estimates of mortality following COVID-19 infection.新冠病毒感染后死亡率的实际估计值。
Lancet Infect Dis. 2020 Jul;20(7):773. doi: 10.1016/S1473-3099(20)30195-X. Epub 2020 Mar 12.
8
Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response.意大利伦巴第大区新冠疫情期间的重症监护利用情况：应急响应中的早期经验与预测
JAMA. 2020 Apr 28;323(16):1545-1546. doi: 10.1001/jama.2020.4031.
9
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局：一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
10
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.KEYNOTE-010 研究中既往接受治疗的程序性死亡受体-1 阳性、晚期非小细胞肺癌患者的长期结局和再次治疗。
J Clin Oncol. 2020 May 10;38(14):1580-1590. doi: 10.1200/JCO.19.02446. Epub 2020 Feb 20.